Theolytics
UK - OxfordBiotechnology
Focus: Theolytics is a UK-based biotechnology company specializing in oncolytic adenovirus therapies for oncology. As a public company founded in 2000, it operates in the specialized immunotherapy space with a focused pipeline in cancer indications.
Profile data last refreshed 12h ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Open Jobs
0
About Theolytics
AI assessmentNot HiringNo open roles listed right now. Follow Theolytics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
THEO-260
Ovarian CancerClinical Trials (1)
NCT07211659Trial of THEO-260 (Administered Via Intraperitoneal Route) in Ovarian Cancer Patients
Phase 1Help build intelligence for Theolytics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.